A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
National Institutes of Health Clinical Center (CC)
Seagen Inc.
Pliant Therapeutics, Inc.
National Cancer Institute (NCI)
OncoC4, Inc.
Genmab
Mayo Clinic
Rutgers, The State University of New Jersey
Sotio Biotech Inc.
Roswell Park Cancer Institute
Dragonfly Therapeutics
Roswell Park Cancer Institute
Dana-Farber Cancer Institute
PMV Pharmaceuticals, Inc
NeoImmuneTech
Merck Sharp & Dohme LLC
National Institutes of Health Clinical Center (CC)
University of Pittsburgh
M.D. Anderson Cancer Center
Tizona Therapeutics, Inc
BioInvent International AB
Essen Biotech
Ohio State University Comprehensive Cancer Center
IDEAYA Biosciences
Eli Lilly and Company
Seagen Inc.
Novartis
Obstetrics & Gynecology Hospital of Fudan University
Merck Sharp & Dohme LLC
Sotio Biotech Inc.
BicycleTx Limited
Merck Sharp & Dohme LLC
Maastricht University Medical Center
Merck Sharp & Dohme LLC
Eli Lilly and Company
University Health Network, Toronto
University of Washington
Mural Oncology, Inc
Merck Sharp & Dohme LLC
Toray Industries, Inc
Medicenna Therapeutics, Inc.
M.D. Anderson Cancer Center
OncoC4, Inc.
North Eastern German Society of Gynaecological Oncology
Compugen Ltd
Carisma Therapeutics Inc
NextCure, Inc.
ARCAGY/ GINECO GROUP
Five Prime Therapeutics, Inc.